title: Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study.
abstract: Our aim was to assess the feasibility of using leucocyte-rich and platelet-rich fibrin (L-PRF) for the treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in a single group study. After treatment with L-PRF, the response of each patient was recorded 1 month and 4 months postoperatively. Further assessments were made of the site, stage, concentration of c-terminal crosslinked telopepide of type 1 collagen, and actinomycosis. Among the total of 34 patients, 26 (77%) showed complete resolution, 6 (18%) had delayed resolution, and 2 (6%) showed no resolution. There was a significant association between the response to treatment and the stage of BRONJ (p=0.002) but no other significant associations were detected. This study has shown that it is feasible to use L-PRF for the treatment of BRONJ, but the effectiveness cannot be judged with this study design. Randomised prospective trials are needed to confirm this.
authors.affiliation: Department of Oral and Maxillofacial Surgery, Ewha Womans University, Seoul, Korea.
authors.forename: Jin-Woo
authors.initials: JW
authors.lastname: Kim
authors.affiliation: Department of Oral and Maxillofacial Surgery, Ewha Womans University, Seoul, Korea. Electronic address: oralsurgeonsj@gmail.com.
authors.forename: Sun-Jong
authors.initials: SJ
authors.lastname: Kim
authors.affiliation: Department of Oral and Maxillofacial Surgery, Ewha Womans University, Seoul, Korea.
authors.forename: Myung-Rae
authors.initials: MR
authors.lastname: Kim
mesh_terms: D000196:Actinomycosis / Q000473:pathology; D000368:Aged; D001706:Biopsy / Q000379:methods; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000145:classification / Q000601:surgery / Q000628:therapy*; D001792:Blood Platelets / Q000502:physiology*; D024042:Collagen Type I / Q000097:blood; D003646:Debridement / Q000379:methods; D005240:Feasibility Studies; D005260:Female; D005337:Fibrin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007962:Leukocytes / Q000502:physiology*; D008336:Mandibular Diseases / Q000145:classification / Q000601:surgery / Q000628:therapy; D008439:Maxillary Diseases / Q000145:classification / Q000601:surgery / Q000628:therapy; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D010865:Pilot Projects; D011446:Prospective Studies; D007507:Therapeutic Irrigation / Q000379:methods; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology
chemical_list: D024042:Collagen Type I; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D005337:Fibrin
keywords: Bisphosphonate; Growth factor; Osteonecrosis of the jaw; Platelet concentrate; Platelet-rich fibrin